New guidelines from the UK’s National Screening Committee urge that routine prostate cancer screenings be limited to only a select group of men. Specifically, this recommendation targets those who carry a dangerous genetic variant and have a significant family history of cancer. According to health advisors, screening should only be available for a small number, estimated to be ‘a few thousand’ men per year.
The Risks of Screening
While prostate cancer screening can potentially save lives, the committee highlights that for most men, the risks may outweigh the benefits. Prostate cancer is the most prevalent cancer among men in the UK, resulting in approximately 12,000 deaths annually. The screening process generally involves a blood test measuring prostate-specific antigen (PSA) levels, followed by an MRI scan if results indicate abnormality.
Recent comprehensive reviews indicate that screening 1,000 men in their 50s could prevent two fatalities from prostate cancer over a span of 15 years. However, it also leads to 20 men being diagnosed with a slow-growing cancer, which may never pose a threat during their lifetimes. Many of these men will receive unnecessary treatments that come with risks of serious side effects, such as erectile dysfunction and incontinence.
Who Should Be Screened?
- Men with a confirmed BRCA2 gene variant and a family history of breast, ovarian, pancreatic, or prostate cancer.
- Men already involved in NHS genetics clinics may be eligible for informal screenings.
Notably, the new guidance does not support screening for:
- All other men without specific risk factors.
- Black men, despite being at a higher risk of developing prostate cancer.
- Men with common family histories of cancer, as it does not significantly narrow down risk.
According to Prof Sir Mike Richards, chairman of the screening committee and a prostate cancer patient, there is still much uncertainty surrounding which prostate cancers require treatment versus those that do not. “The treatments available can result in long-lasting harm,” he explains.
Ongoing Evaluations and Future Prospects
The committee will continue to monitor emerging evidence and advancements in testing technologies that may support more comprehensive screening programs in the future. New methods, including artificial intelligence tools, are under consideration, alongside findings from clinical trials aimed at better outcomes for high-risk groups, notably Black men.
Despite the limited scope of this screening recommendation, advocates like Olympian Sir Chris Hoy and public figures such as Stephen Fry have raised awareness about the importance of early detection in the fight against prostate cancer. Many voices have echoed the need for broader access to screening amidst concerns about the increasing number of men affected by this disease.
As the healthcare landscape evolves, experts hope that improvements in understanding prostate cancer will eventually lead to expanded screening protocols.
Source: BBC News
Source: BBC News - Health
